These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 11029503

  • 1. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
    Toma S, Raffo P, Nicolo G, Canavese G, Margallo E, Vecchio C, Dastoli G, Iacona I, Regazzi-Bonora M.
    Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
    Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R.
    Clin Cancer Res; 1998 Mar; 4(3):635-42. PubMed ID: 9533531
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer.
    Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O'Brien M, Murphy RF, Balis FM.
    J Clin Oncol; 1997 Nov; 15(11):3330-7. PubMed ID: 9363862
    [Abstract] [Full Text] [Related]

  • 4. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
    Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM.
    J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529
    [Abstract] [Full Text] [Related]

  • 5. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.
    Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus DM, Scher HI.
    Clin Cancer Res; 2000 Mar; 6(3):838-46. PubMed ID: 10741705
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
    Park SH, Gray WC, Hernandez I, Jacobs M, Ord RA, Sutharalingam M, Smith RG, Van Echo DA, Wu S, Conley BA.
    Clin Cancer Res; 2000 Mar; 6(3):847-54. PubMed ID: 10741706
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.
    Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.
    Cancer; 2002 Sep 15; 95(6):1220-7. PubMed ID: 12216088
    [Abstract] [Full Text] [Related]

  • 8. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
    Wadler S, Schwartz EL, Haynes H, Rameau R, Quish A, Mandeli J, Gallagher R, Hallam S, Fields A, Goldberg G, McGill F, Jennings S, Wallach RC, Runowicz CD.
    Cancer; 1997 Apr 15; 79(8):1574-80. PubMed ID: 9118041
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations.
    Lawrence JA, Adamson PC, Caruso R, Chow C, Kleiner D, Murphy RF, Venzon DJ, Shovlin M, Noone M, Merino M, Cowan KH, Kaiser M, O'Shaughnessy J, Zujewski J.
    J Clin Oncol; 2001 May 15; 19(10):2754-63. PubMed ID: 11352969
    [Abstract] [Full Text] [Related]

  • 10. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study.
    Miller WH, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, Cato A, Jaunakais D, Truglia JA, Matthews S, Dancey J, Eisenhauer E.
    Ann Oncol; 2000 Nov 15; 11(11):1387-9. PubMed ID: 11142476
    [Abstract] [Full Text] [Related]

  • 11. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma.
    Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, Murphy RF, Cohen RB, Broder S, Yarchoan R.
    J Clin Oncol; 1995 Aug 15; 13(8):1966-74. PubMed ID: 7636537
    [Abstract] [Full Text] [Related]

  • 12. Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer.
    Falanga A, Toma S, Marchetti M, Palumbo R, Raffo P, Consonni R, Marziali S, Dastoli G, Barbui T.
    Am J Hematol; 2002 May 15; 70(1):9-15. PubMed ID: 11994976
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993).
    Dutcher JP, Lee S, Gallagher RE, Makary AZ, Hines JD, Londer H, Farnen JP, Bennett JM, Paietta E, Rowe JM, Goloubeva O, Wiernik PH, Eastern Cooperative Oncology Group.
    Leuk Lymphoma; 2005 Mar 15; 46(3):377-85. PubMed ID: 15621827
    [Abstract] [Full Text] [Related]

  • 14. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
    Chiesa MD, Passalacqua R, Michiara M, Franciosi V, Di Costanzo F, Bisagni G, Camisa R, Buti S, Tomasello G, Cocconi G, Italian Oncology Group for Clinical Research.
    Acta Biomed; 2007 Dec 15; 78(3):204-9. PubMed ID: 18330080
    [Abstract] [Full Text] [Related]

  • 15. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
    Seymour L, Bezwoda WR.
    Br J Cancer; 1993 Aug 15; 68(2):352-6. PubMed ID: 8347490
    [Abstract] [Full Text] [Related]

  • 16. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
    Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM.
    Clin Cancer Res; 2002 Sep 15; 8(9):2835-42. PubMed ID: 12231524
    [Abstract] [Full Text] [Related]

  • 17. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M.
    Leuk Lymphoma; 1999 Nov 15; 35(5-6):483-9. PubMed ID: 10609785
    [Abstract] [Full Text] [Related]

  • 18. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest.
    Yang L, Ostrowski J, Reczek P, Brown P.
    Oncogene; 2001 Nov 29; 20(55):8025-35. PubMed ID: 11753686
    [Abstract] [Full Text] [Related]

  • 19. All-trans retinoic acid potentiates cisplatin-induced kidney injury in rats: impact of retinoic acid signaling pathway.
    Elsayed AM, Abdelghany TM, Akool el-S, Abdel-Aziz AA, Abdel-Bakky MS.
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Mar 29; 389(3):327-37. PubMed ID: 26659823
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.
    Sutton LM, Warmuth MA, Petros WP, Winer EP.
    Cancer Chemother Pharmacol; 1997 Mar 29; 40(4):335-41. PubMed ID: 9225952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.